Vivaldi Capital Management’s Gilead Sciences GILD Stock Holding History

Vivaldi Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,743	Closed	-$280K	–	276
2020 Q1	$280K	Buy	3,743 +351	+10%	+$24.3K	0.06%	158
2019 Q4	$220K	Sell	3,392 -717	-17%	-$46.7K	0.05%	194
2019 Q3	$260K	Buy	4,109 +740	+22%	+$48.4K	0.06%	180
2019 Q2	$228K	Buy	+3,369	New	+$222K	0.06%	204
2018 Q4	–	Sell	-2,826	Closed	-$218K	–	206
2018 Q3	$218K	Buy	+2,826	New	+$213K	0.12%	122
2018 Q2	–	Sell	-2,736	Closed	-$206K	–	147
2018 Q1	$206K	Buy	+2,736	New	+$217K	0.15%	119
2017 Q4	–	Sell	-4,707	Closed	-$381K	–	144
2017 Q3	$381K	Buy	4,707 +80	+2%	+$6.12K	1.64%	28
2017 Q2	$327	Buy	+4,627	New	+$308K	﹤0.01%	67

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Vivaldi Capital Management's GILD Position: Q2 2020 in Review

Vivaldi Capital Management sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 3,743 shares — an estimated $280K sold.

Vivaldi Capital Management first reported a position in GILD in Q2 2017 and held it in 8 quarters. The position peaked at $381K in Q3 2017. 1,625 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

Vivaldi Capital Management reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
Vivaldi Capital Management sold 3,743 Gilead Sciences shares in Q2 2020, an estimated $280K.
Vivaldi Capital Management first reported a position in Gilead Sciences in Q2 2017 and held it in 8 quarters.
Vivaldi Capital Management's Gilead Sciences position peaked at $381K in Q3 2017.
1,625 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Vivaldi Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.